The Pulmonary Hypertension Association (PHA) encourages pulmonary hypertension professionals to apply for two research grants. They are: Early Career Mentored Scientist Award ($65,000 for one year) and Innovation Research Award ($60,000 a year for two years).
The Pulmonary Hypertension Association (PHA)'s PH Professional Network (PHPN) Symposium will include a session on wellness and mental health for pulmonary hypertension (PH) providers and patients. The event is Sept. 28-30 in Arlington, Virginia. Registration opens this month.
The Pulmonary Hypertension Association (PHA) is pleased to announce Paul Crister, M.D., Ph.D., as the recipient of the 2022 Pediatric PH Research Award. The research award supports research that could have a great impact toward advancing the field of PH pediatrics.
Pulmonary hypertension (PH) health professionals can meet the primary author of recently released PH guidelines at the PH Professional Network Symposium. Dr. Marc Humbert will discuss the new PH guidelines during the Sept. 28-30 PHA event in Arlington, Virginia. The guidelines, developed by a taskforce from the European Society of Cardiology and European Respiratory Society, were published in August 2022.
The Pulmonary Hypertension Association added three new courses on Genetics and PH to its Online University. Watch the videos to earn 2.75 continuing education credits.
The Pulmonary Hypertension Association is accepting applications for a new grant to support junior pulmonary hypertension researchers. Apply now, or spread the word about PHA’s Early Career Mentored Scientist Award. The one-year grant covers up to $65,000 for PH-related research projects that have been favorably reviewed but not funded by the National Institutes of Health. Apply by March 20.
A manufacturer recall of specific lots of CADD infusion systems recommends against using the affected systems for life-sustaining medication including brand and generic treprostinil (Remodulin) and epoprostenol (Veletri, Flolan).Patients contacted by their specialty pharmacy or PH care team about the issues described below should follow the provided directions immediately.
The 2019 Pulmonary Hypertension Professional Network (PHPN) Symposium, “Influencing the Practice: The Art and Science of Treating Pulmonary Hypertension,” kicks off today. More than 400 medical professionals from all over the U.S. have gathered in Washington, D.C., for this biennial event. We are looking forward to a busy and invigorating three days of education
What’s in store at the Pulmonary Hypertension Association’s PH Professional Network (PHPN) Symposium “Influencing the Practice: The Art and Science of Treating Pulmonary Hypertension,” Sept. 5-7, in Washington, D.C.? Plenty! Session topics for health care professionals range from overcoming insurance challenges to women’s issues in pulmonary hypertension (PH) and more. Scheduled sessions earn attendees
Volume 18, Issue 1 of Advances in Pulmonary Hypertension, “PH in Congenital Heart Disease (CHD),” guest edited by Dunbar Ivy, M.D., is dedicated to the transition between child and adult with pulmonary hypertension (PH) and congenital heart disease and the gaps in knowledge and differences in treatment guidelines between children and adults. Depending on
